Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Agios Pharmaceuticals, Inc. AGIO
$25.37
-$0.01 (-0.06%)
На 18:00, 12 мая 2023
+73.43%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
1413975552.00000000
-
week52high
34.76
-
week52low
16.75
-
Revenue
14240000
-
P/E TTM
-19
-
Beta
0.95328700
-
EPS
-4.23000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:00
Описание компании
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 05 авг 2022 г. |
| SVB Leerink | Outperform | Market Perform | 27 июл 2022 г. |
| Goldman Sachs | Sell | Sell | 24 мая 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 17 мая 2022 г. |
| Goldman Sachs | Sell | Sell | 07 мар 2022 г. |
| Goldman Sachs | Neutral | Sell | 17 ноя 2022 г. |
| JP Morgan | Neutral | Neutral | 01 дек 2022 г. |
| Piper Sandler | Overweight | 03 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Schenkein David P | D | 96363 | 20000 | 30 янв 2023 г. |
| Schenkein David P | D | 117879 | 3300 | 30 янв 2023 г. |
| Schenkein David P | D | 121179 | 16700 | 30 янв 2023 г. |
| Schenkein David P | A | 137879 | 20000 | 30 янв 2023 г. |
| Schenkein David P | D | 116363 | 20000 | 17 янв 2023 г. |
| Schenkein David P | D | 117879 | 1034 | 17 янв 2023 г. |
| Schenkein David P | D | 118913 | 18966 | 17 янв 2023 г. |
| Schenkein David P | A | 137879 | 20000 | 17 янв 2023 г. |
| Foster-Cheek Kaye I | D | 6549 | 2200 | 13 янв 2023 г. |
| Milanova Tsveta | A | 25426 | 25426 | 03 янв 2023 г. |
Новостная лента
Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress
GlobeNewsWire
11 мая 2023 г. в 10:00
– Agios to Present New Analyses from ACTIVATE, ACTIVATE-T and Long-Term Extension Studies in Adults with PK Deficiency Reinforcing Clinical Benefit of PYRUKYND ® (mitapivat) on Hemoglobin, Hemolysis, Iron Overload and Patient-Reported Outcomes –
Wall Street Analysts Predict a 42.46% Upside in Agios Pharmaceuticals (AGIO): Here's What You Should Know
Zacks Investment Research
09 мая 2023 г. в 11:27
The consensus price target hints at a 42.5% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Zacks Investment Research
05 мая 2023 г. в 12:09
Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
GlobeNewsWire
25 апр 2023 г. в 07:00
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2024, at 9 a.m. ET.
Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023
GlobeNewsWire
13 апр 2023 г. в 07:00
CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 4, 2023, at 8:00 a.m. ET to report its first quarter 2023 financial results and other business highlights.